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 ABSTRACT 
The purpose of this study was to study the basic cellular indicators of 
immunity in patients with non-Hodgkin's lymphomas to substantiate the 
immunopathogenetic features of the course of the disease. It turned out to be 
important that patients were divided into 2 groups with virus carrier and 
without virus carrier. 
An analysis of the results allowed us to identify pronounced changes in the 
cellular immunity that manifested themselves by suppressing the expression of 
CD3 +, CD3 + CD4 +, IRI, against this background, an increase in the expression 
of CD3 + CD8 +, CD16 + and CD20 + B cells, as well as increased expression of 
activation molecular markers of CD38 + lymphocytes, CD95 +. Deep T-cell 
immunodeficiency was detected against the background of pathological 
activation of lymphocytes, which is clinically often reflected by frequent 
relapses, an unfavorable course of the disease, and treatment results. 
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Non-Hodgkin's lymphomas (NHL) - a heterogeneous group of tumors of the blood system, 
characterized by various clinical course, localization, morphological, immunological; cytogenetic 
features, and results of therapy [12,16]. In recent years, the incidence of NHL has increased 
[6,10,13,15]. Men get sick about 3 times more often than women [1,2,4,7,9,9,14]. 
Cells of various morphoimmunological characteristics are the substrate of NHL, modern ideas about 
which allow us to rethink the basics of isolation! and the systematization of various options for NHL 
[1,5,7,8]. The last years of the development of oncohematology were marked by the emergence of new 
research methods: immunophenotyping, immunohistochemistry, molecular genetics, which along with 
morphological studies contributed to a deeper understanding of the pathogenetic mechanisms of the 
formation of NHL. This is reflected in modern classifications of lymphomas (classification of the European-
American group for the study of lymphomas 1994., classification of tumors of the hematopoietic and 
lymphoid tissues of the WHO, 2001, 2008). The use of immunodiagnostics methods led to the isolation of 
T-, B- and cellular NHL, and within each group - several options (from immunologically immature and 
mature cells) [9,11,12,16]. Later, taking into account the expression of certain clusters of cell differentiation, 
some variants were transformed into separate nosological units: primary mediastinal (thymic) B-large cell 
lymphoma (BLCL), anaplastic large-cell lymphoma (LCL) positive and negative [1,2,4,7, 9.14]. In 
childhood, lymphoblastic lymphomas from progenitor cells (LBL) are most often diagnosed, and from 
mature cell NHL, Burkitt’s lymphoma (BL), LCL characteristics of the tumor, in particular, the group. Only 
an integrated approach that takes into account the peculiarities of the morphological picture and uses an 
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expanded diagnostic immunological panel of antibodies, which is aimed at identifying not only the markers 
of mature T and B cells, but also the antigens of progenitor cells, makes it possible to correctly diagnose 
[4,5,7,10]. The main treatments for NHLremain polychemotherapy and radiation therapy. Isolation of new 
nosological forms in NHL group led to the emergence of various PCT programs followed by their gradual 
intensification (COP, COMP, LMB-81.84.86.89, NHL-BFM90 / 95) [12.16]. 
Based on the immunological characteristics of tumor cells, targeted drugs - monoclonal antibodies 
(anti-C020 - rituximab, zevalin, anti-CD22 - epratuzumab) have now begun to be used for therapeutic 
purposes. As a result of the use of modern therapy programs, the indicators of the overall, event-free and 
relapse-free survival of individuals with NHL have improved, reaching by now 85-91% [2.6]. The use of 
targeted therapy has improved B-NHL treatment outcomes. However, the problem of improving treatment, 
which directly depends on the state of the immune system, the presence and degree of secondary 
immunodeficiency, and the individual development of the disease, remains urgent. 
At present, great attention is paid to the study of immunological mechanisms in the 
development and progression of lymphomas. An important issue remains the immunodiagnostics of 
cellular and humoral immunity. As the literature shows, publications devoted to the study of immunity 
are sporadic. Basically, articles are devoted to clinical study and the description of the results of 
treatment methods, while there are no works of a pathogenetic nature. Reliable data can only be 
obtained by analyzing a sufficiently large amount of clinical material, which makes it possible to study 
the frequency of occurrence of various NHL variants; comparison of clinical, morphological and 
immunological data, as well as treatment results for T- and B-cell lymphomas, which opens up the 
possibility of improving the diagnosis and individualization of chemotherapy programs depending on 
the immunophenotypic characteristics of tumor cells. 
The aim of the study. To study the basic cellular indicators of immunity in patients with non-
Hodgkin's lymphomas to substantiate the immunopathogenetic features of the course of the disease. 
Materials and research methods. In our study, patients with non-Hodgkin’s lymphomas (NHL) 
were divided into 2 groups: group I - patients with established virus carriers; group II - patients in the 
control group with no virus carrier. In the distribution of NHL patients by age, it was found that virus 
carriage leads to a rejuvenation of the disease: the peak incidence rate in group I is up to 30 years, while the 
same indicator for group II is over 50 years. The results of the analysis are presented in table 1. 
Table 1. Distribution of patients by age and gender 
Age, years 
group I 
(virus carrier), n=23 
group II 
(control), n=18 
Men Women Men Women 
Abs % Abs % Abs % Abs % 
< 30 11 47,8±7,8 4 17,3±5,9 -  2 11,1±4,9 
31-40 1 4,3±2,2 -  1 5,5±2,7 1 5,5±2,7 
41-50 2 8,6±4,4 1 4,3±2,2 -  1 5,5±2,7 
51-60 1 4,3±2,2 -  5 27,7±6,9 3 16,6±5,8 
61-70 2 8,6±4,4 -  1 5,5±2,7 -  
> 70 1 4,3±2,2 -  3 16,6±5,8 1 5,5±2,7 
The age of sick men with virus-bearing was 35.6 ± 4.56 years, among women - 27.2 ± 5.24 
years, in the control group, the average age of men was 60.7 ± 3.80 years, women - 45.5 ± 6, 97 years 
old. The proportion of women in group I was 21.7 ± 6.44%, men - 78.3 ± 6.44%; in group II, women 
accounted for 44.4 ± 7.75%, men - 55.6 ± 7.75%. 
In all patients, the diagnosis was established on the basis of data and the results of a 
comprehensive study (clinical, biochemical, radiological, ultrasound, CT, myelogram, morphological). 
The lesion areas for non-Hodgkin’s lymphomas in patients with viral infection (group I) most 
often occurred in the cervical and axillary l / nodes (more than 50%), then in the mediastinal, 
supraclavicular, retroperitoneal and inguinal (25-45%), the lesion was least noted. iliac l / nodes, 
spleen, Valdeyer (20% or less). 
In control group II, the picture of lymph node lesions differed from the experimental group − 
patients with affected cervical l / nodes were more than 70%, while the remaining lesion zones were 
less common: axillary, supraclavicular, inguinal l / nodes malignantly transformed in 30-40% of cases; 
mediastinal, retroperitoneal, iliac - in less than 20% of cases; Valdeyer ring damage was observed in 
more than 60% of patients. 
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Thus, viral infection changes the picture of lymph node damage in patients with NHL in 
comparison with patients without viral load: in group I, axillary, mediastinal, supraclavicular, 
retroperitoneal, and retroperitoneal / inguinal l / nodes were transformed malignantly (25-45%). Group 
I patients were most often infected with HSV herpes simplex virus and Epstein-Barr virus (65-80%). 
Cytomegalovirus infection (CMV), human papilloma virus (HPV) in 43.4 ± 7.7% of patients, and 
Varicella-Zoster virus were found in 26.0 ± 6.8% and 8.6 ± 4.4%, respectively. 
The examination included patients undergoing examination in the chemotherapy department. 
All patients underwent clinical and laboratory blood tests, which included the study of a general 
analysis of blood and urine, biochemical and immunological parameters, as well as the blood 
coagulation system. Patients underwent a comprehensive clinical and instrumental examination aimed 
at clarifying the prevalence of the tumor process and identifying existing complications. 
Immunological studies included the study of cellular and humoral parameters of the immune 
system of patients with OC. Determination of cellular immunity (CD3 +, CD3 + CD4 +, CD3 + CD8 +, 
CD16 +, CD20 +), as well as identification of activation markers of lymphocytes (CD25 +, CD38 + and 
CD95 +) was carried out by flow cytometry using Accuri C6 (USA) using monoclonal antibodies. 
When conducting a statistical analysis of the data presented in the work, the results of the 
study were entered into databases prepared in the Microsoft Excel XP program. Numerical 
(continuous) values were presented as arithmetic means and mean errors (M ± m). Comparison of 
quantitative characteristics was carried out using Student's criterion, for continuous variables - paired 
Student's criterion. P <0.05 was taken as a boundary comparative criterion of statistical significance. 
The obtained research results and their discussion. Thanks to the modern achievements of 
fundamental immunology, molecular biology, new biologically significant indicators have now 
appeared in the arsenal of researchers, which can help the practitioner, in particular in the diagnosis, 
treatment and prognosis of diseases, as well as in the choice of immunotropic therapy. In this regard, 
in recent years, much attention has been paid to immunological markers that can help in identifying an 
immunodeficiency state, diagnosing, predicting and preventing relapse of the disease, which is a kind 
of indicator of the nature of the course of the disease, especially in cancer [11,15]. 
The main factors of immunity that have been studied and will be presented below include 
cellular factors of immunity, such as population and subpopulation markers of lymphocytes. It should 
be noted that the listed immunity parameters are specific factors, but studying them against a specific 
nosology and comparing the results with the clinical manifestations of the disease are definitely 
important, specific value, because it is the elements of the immune system that accompany all 
processes of pathogenesis, the development of the disease, its progression and outcome. It is known 
that all malignant processes are related to immunodeficiency conditions, accompanied by 
immunosuppression of any parts of the immune system [6,13]. Therefore, the study of the 
immunoreactivity status of cancer patients is an important factor necessary to establish the depth of 
immunodeficiency, to predict the disease and, most importantly, to identify the most radical methods 
of therapy, including immunotropic therapy in the future. 
The immunological parameters of patients with NHL were analyzed before the start of 
complex treatment to identify pathogenetic characteristics of the response. Analysis of the results 
showed that the average content of leukocytes in peripheral blood in all groups of patients was reduced 
compared with the value of the control group. 
Moreover, a significant decrease in the content of leukocytes was detected in groups of patients 
before treatment compared with data from a group of practically healthy individuals. The highest leukocyte 
count was detected in the group of patients and amounted to 6280.9 ± 280.7cl / µl. The study of the relative 
content of the total pool of lymphocytes between the studied groups of patients showed that the number of 
lymphocytes was significantly suppressed in the group of patients compared with the value of the control 
group. It was found that the most significantly low value of lymphocytes was observed in groups of 
patients before treatment with virus carrier. So, the level of lymphocytes in the group of patients with virus 
carrier was 29.3 ± 1.2%, while in the control group it was 33.8 ± 1.11%. 
It was found that phenotypic markers of lymphocytes include such markers as CD3 +, CD3 + CD4 
+, CD3 + CD8 +, CD20 +. It is widely shown in the literature that the triggering and regulation of the 
effectiveness of the immune response is largely determined by the specific antigen of T-lymphocytes. 
Responsible for this function are antigen-recognizing receptors - TCR. It is known that the degree of surface 
expression of CD3 + receptors on the membrane of T-lymphocytes reflects its transmissible function and 
allows to identify the total number of T-lymphocytes [3,12]. Thus, the analysis of the immunophenotype of 
CD3 + T-lymphocytes in patients with NHL showed that the presence of a reliable suppression of the 
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expression of CD3 + on T-lymphocytes is observed in all groups of patients compared with data from a 
practically healthy group (p <0.05). The lowest CD3 + value was observed in the group of patients with 
virus carriers before chemotherapy. Obviously, a decrease in the total pool of T-lymphocytes (CD3 +) was 
observed mainly due to the suppression of the expression of CD3 + CD4 +. A study of the expression of 
CD3 + CD4 + on T-lymphocytes, which are the main regulatory cells of the immune system, showed that 
the lowest value was noted in groups of patients before treatment (p <0.05). The expression of CD3 + CD4 + 
was most suppressed in the group of patients with NHL with virus carrier. It has been shown in the literature 
that the CD4 + T-cell response to tumor proteins is an important cellular defense mechanism of the 
macroorganism, since CD4 + T-helpers stimulate antibody production by B-lymphocytes and activate CD8 
+ T-lymphocytes specific for tumor cells [2,5, 7,9,13]. The analysis showed that in the group of patients with 
virus-bearing CD3 + CD4 + it was 21.4 ± 1.3%, while in the groups of patients without virus-bearing it was 
25.8 ± 0.8%, and in the group of practically healthy individuals it was 35.7 ± 1.14%. 
Cytotoxic CD3 + CD8 + T-lymphocytes play an important role in the pathogenesis of cancer 
[4,8]. It is proved that the function of these cells is the recognition of antigens on the cell surface in 
combination with MHC class 1 molecules. Since they are present on almost all nuclear cells of the 
body, any cell carrying MHC class 1 molecules in combination with an antigenic peptide can activate 
a clone of cytotoxic T lymphocytes. The biological role of this activation is the removal of mutant 
cells [4,9]. CD3 + CD8 + T-lymphocytes play a major role in the elimination of the virus, which is 
caused, on the one hand, by their ability to cause the death of infected cells expressing the 
corresponding peptides presented by MHC class 1 molecules, and, on the other hand, the ability to 
secrete antitumor factors - cytokines [4, 7, 11, 16]. 
Analysis of the expression of CD3 + CD8 + on T-lymphocytes revealed a significant increase in 
all groups of patients compared with the value of the control group. It should be noted that the maximum 
increase in CD3 + CD8 + was detected in the group of patients before treatment (p <0.05). An analysis 
of the values of CD3 + CD8 + on T-lymphocytes between the studied groups of patients shows that 
before treatment, the expression of CD3 + CD8 + was significantly increased and amounted to 37.9 ± 
1.72%. The immunoregulatory index (IRI), which is the ratio of the values of CD3 + CD4 + / CD3 + 
CD8 +, is of significant importance in secondary immunodeficiency states. It is known that in normal IRI 
in healthy individuals averages 1.62 ± 0.02. Obviously, suppression of the expression of CD3 + CD4 + 
against the background of increased expression of CD3 + CD8 + leads to a decrease in IRI. According to 
our data, the lowest decrease in IRI is observed in the group of patients before treatment with virus-
bearing compared with the data of patients without virus-bearing (p <0.05). Therefore, pronounced 
immunosuppression was characteristic of patients with NHL in groups of patients before treatment with 
virus carrier. Apparently, a decrease in IRI is an important criterion for the depth of the T - cell 
immunodeficiency state, especially against the background of infection with latent chronic viruses. 
Further, the expression of killer cells, which are the third population of lymphocytes providing 
maintenance of genetic homeostasis, which are phenotypically and functionally significantly different from 
T and B lymphocytes, was studied [5,8]. Killer lymphocytes belong to the category of the main effectors of 
natural or innate immunity, which are able to lyse target cells or carry out antibody-dependent cellular 
cytotoxicity. They perform the functions of the first line of defense before immune T-lymphocytes and 
specific antibodies arise [5,7]. Killer cells with CD16 + phenotypes were studied. A significant increase in 
the expression of CD16 + was revealed in all groups of patients. It was shown that the highest expression of 
CD16 + is observed in the group of patients with virus carrier (p <0.05). So, in the group of patients before 
treatment, the expression of CD16 + was 27.6 ± 1.1%, in the control group (without virus carrier) - 24.5 ± 
1.31%, in the group of practically healthy individuals - 16.7 ± 1.4%. Consequently, the highest expression 
of CD16 + was observed in groups of patients prior to the start of chemotherapy with virus carrier. 
A study of the expression of CD20 + on B-lymphocytes, which are the main regulatory cells of the 
immune system and are important in the development of humoral immunity, showed that the expression of 
CD20 + was significantly increased in all groups of patients (p <0.05). Despite this, the study of the content of 
B-lymphocytes is an important criterion to assess the depth of immunodeficiency and determine the next steps 
in terms of diagnosis and treatment. Next, activation markers of peripheral blood lymphocytes were studied. It 
is known that the activation markers of lymphocytes began to be studied relatively recently, therefore, small 
works on the functional activity of activation markers of lymphocytes, in particular in oncological processes, 
have been reported in the literature [15,16]. From the available literature data, it is clear that the study of 
activation markers of lymphocytes, especially in proliferative processes, is of great scientific and practical 
importance. analysis of activation markers of lymphocytes allows one to study the processes of activation, 
proliferation, differentiation, and apoptosis of immunocompetent cells and characterizes cell cycles associated 
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with these processes [6,7]. So, we studied lymphocyte markers such as CD38 + and CD95 +. It is known that 
CD38 + is an activation marker represented by a transmembrane glycoprotein, which is considered as a 
multifunctional protein [14,16]. The enzymatic functions of CD38 + provide its main immunoregulatory role; 
this is the binding of various agents to this receptor, which enhances the synthesis of cytokines, activation of 
kinases, and protein phosphorylation [6, 9]. CD38 + is expressed on immature T- and B-lymphocytes, 
activated T-lymphocytes, plasmocytes [15]. Analysis of the expression of CD38 + on lymphocytes revealed a 
significant increase in this marker in groups of patients before treatment. The highest value of CD38 + was 
observed in groups of patients before treatment with virus carrier. The expression of CD38 + before treatment 
was 33.2 ± 1.7%, without virus carrier - 28.4 ± 1.5%, and normal - 23.4 ± 0.6%. Therefore, increased 
expression of CD38 + was observed before the treatment of patients, which is apparently associated with the 
proliferative activity of specific T and B lymphocytes in response to the malignant process and chronic virus 
carriage. Also, increased expression of CD38 + may be associated with activation of CD3 + CD8 +, CD16 + 
and CD20 +. According to published data, there is information about the role of APO-1 / Fas (CD95 +) 
receptors in the process of apoptosis, and its degree is a reflection of the level of lymphocyte apoptosis [3,6]. It 
has been established that an increase in the expression of CD95 + receptors on lymphocytes indicates an 
excessive and ineffective process of stimulating blood lymphocytes, which indicates an apoptotic pathway for 
the death of lymphocytes [16]. Binding of CD95 + to the Fas ligand induces apoptosis of cells expressing 
CD95 +. The analysis showed that in groups of patients increased expression of CD95 + is noted. Moreover, 
the greatest expression is observed in groups of patients before treatment with virus carrier. Apparently, 
excessive apoptosis in combination with the activation of the humoral immunity and deep T-cell 
immunodeficiency contribute to the progression of the disease. 
Thus, the analysis of the results allowed us to identify pronounced changes in the cellular 
component of immunity, which are manifested by a suppression of the expression of CD3 +, CD3 + 
CD4 +, IRI, increased expression of CD3 + CD8 +, CD16 + and CD20 + cells, as well as increased 
expression of CD38 +, CD95 +. 
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